EN
Anticancer Activity of Calcium Channel Blockers in Colon Cancer Cell Culture
Abstract
Objective: Repurposing non-cancer drugs for cancer treatment has many advantages. We can access to a new cancer drug easily, quickly and cheaply. In addition, we generally know safety prifile of repurped drugs. There are few studies in the literature investige the anticancer effects of Calcium channel blockers (CCBs). We planned to investigate the anticancer effects of CCBs on colon cancer cell line.
Material and Method: We adminestered different doses of T-type CCB NNC-55-0396 and L-type CCB amlodipine on colon cancer cell line HT-29. MTT analysis was performed at 48 hours to measure cell viability. The dose-response curve was constructed using GraphPad Prism.8 programme.
Results: Amlodipine caused more than 90% cytotoxicity at all concentrations of 500, 250, 100, 50, 10 µg/ml in MTT analysis at 48 hours. Similarly, NNC-55-0396 caused more than 90% cytotoxicity at all 80, 40, 20, 10.5 µM concentrations.
Discussion: In our study, NNC-55-0396 and amlodipine molecules showed severe cytotoxicity on HT-29 cells. There are publications indicating that it may have other anticancer effects other than cytotoxicity. They are promising molecules as anti-cancer drugs. They should be investigated in clinical studies alone or in combination with other cancer drugs.
Material and Method: We adminestered different doses of T-type CCB NNC-55-0396 and L-type CCB amlodipine on colon cancer cell line HT-29. MTT analysis was performed at 48 hours to measure cell viability. The dose-response curve was constructed using GraphPad Prism.8 programme.
Results: Amlodipine caused more than 90% cytotoxicity at all concentrations of 500, 250, 100, 50, 10 µg/ml in MTT analysis at 48 hours. Similarly, NNC-55-0396 caused more than 90% cytotoxicity at all 80, 40, 20, 10.5 µM concentrations.
Discussion: In our study, NNC-55-0396 and amlodipine molecules showed severe cytotoxicity on HT-29 cells. There are publications indicating that it may have other anticancer effects other than cytotoxicity. They are promising molecules as anti-cancer drugs. They should be investigated in clinical studies alone or in combination with other cancer drugs.
Keywords
References
- 1. Corsello, S.M., et al., Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nature cancer, 2020. 1(2): p. 235-248.
- 2. Alandağ, C., E. Karaman, and E. Yüce, Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer. Anti-Cancer Drugs, 2022. 33(4): p. 389-393.
- 3. Alandağ, C., E. Merev, and F. Özdemir, Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer. Anticancer Drugs, 2021.
- 4. Shiozaki, A., et al., Amlodipine and Verapamil, Voltage-Gated Ca(2+) Channel Inhibitors, Suppressed the Growth of Gastric Cancer Stem Cells. Ann Surg Oncol, 2021. 28(9): p. 5400-5411.
- 5. Panneerpandian, P., D.B. Rao, and K. Ganesan, Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicol In Vitro, 2021. 74: p. 105152.
- 6. Yoshida, J., et al., Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells. Life Sci, 2010. 86(3-4): p. 124-32.
- 7. Huang, W., et al., T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines. Journal of Experimental & Clinical Cancer Research, 2015. 34(1): p. 54.
- 8. Bong, A.H.L. and G.R. Monteith, Calcium signaling and the therapeutic targeting of cancer cells. Biochim Biophys Acta Mol Cell Res, 2018. 1865(11 Pt B): p. 1786-1794.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
October 1, 2022
Submission Date
September 11, 2022
Acceptance Date
September 26, 2022
Published in Issue
Year 1970 Volume: 44 Number: 3